natural glp-1 receptor agonists Crystal structure of the bound to a peptide agonist GLP-1 Receptor Agonists as Treatments

doi: 10.1016/S2213-8587(19)30180-9

The commercial potential tied to GLP-1 therapies is expanding quickly, with the global GLP-1 market forecast to potentially reach $190 billion by 2035

Two of the most talked-about medications in this area are Mounjaro and Ozempicboth injectable treatments that have demonstrated impressive results in clinical studies

This formulation includes a small fatty acid permeation enhancer, SNAC, that promotes absorption of semaglutide across the stomach mucosa and into systemic circulation

Since GLP-1 drugs have been in shortage since 2022, several companies such as Hims & Hers, Ro, and WeightWatchers have had greater latitude to offer compounded versions of the drugs to meet the increased demand at a much lower cost than the popular brand name versions

The early clinical adoption suggests that some practitioners believe the potential benefits outweigh the risks